Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
about
Design and pre-clinical evaluation of a universal HIV-1 vaccineProtective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccineViral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization BreadthSignificantly longer envelope V2 loops are characteristic of heterosexually transmitted subtype B HIV-1 in TrinidadCCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infectionA directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoproteinProgress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility.HIV-1 vaccine development after STEP.Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopesHSV type 2 infection increases HIV DNA detection in vaginal tissue of mice expressing human CD4 and CCR5Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains.Rational antibody-based HIV-1 vaccine design: current approaches and future directionsGlycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection.GPI-anchored single chain Fv--an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike.Generation and characterization of an HIV-1 subtype C transmitted and early founder virus consensus sequence.Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaquesDNA vaccines: ready for prime time?A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women.Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16.Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component.Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccineMutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses.Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 is a potent HIV-1 entry inhibitorDelivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responsesDNA prime-protein boost using subtype consensus Env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China.A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys.Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge.Role of the HIV gp120 conserved domain 1 in processing and viral entry.Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccinationViral sequence diversity: challenges for AIDS vaccine designs.T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.Retrovirus glycoprotein functionality requires proper alignment of the ectodomain and the membrane-proximal cytoplasmic tailDiverse viral glycoproteins as well as CD4 co-package into the same human immunodeficiency virus (HIV-1) particles.Therapeutic and prophylactic DNA vaccines for HIV-1.
P2860
Q21092234-26F7E9AD-8B3F-42B3-A549-BDA3992644B9Q21131325-B41A619B-F5AB-4CE8-9576-FC690D5E450AQ27676728-5325F254-A126-4FB5-81C0-350EFFDB51B0Q28478624-634EF890-D7DB-4937-80A0-84594BB6ADE0Q28542878-A8A7B9A0-7485-42BC-86A0-D4B4FB02B7A1Q28743092-1B7441EF-A5A7-41D7-9F80-9F13F1C770A6Q30379200-13A52591-601E-49BB-AC45-25EDCDFF7FE3Q33323199-56821629-2411-461A-A598-4730E331D4D8Q33642318-A815B897-4EF6-487C-A414-882FAF64234EQ33648910-31DE0DA7-AF7D-4227-A8ED-918D38563136Q33680806-6B68BE17-4431-422E-80BD-9576B66E77F5Q33872445-AF29E9A4-AF68-4ED2-86A4-E299B9509143Q33937285-694C8303-2C70-4D1D-B338-22D0252C65C2Q33967039-D6A794D5-B0C0-4C37-ABA4-852EEB10E6D6Q34034659-62EF92A0-25F9-4BB4-9DDA-69A8F575DFF2Q34221625-92558B80-7F15-4252-97D0-48B872D347DAQ34266252-C308C500-FA9A-4D1E-A1EA-8090E1BEF2CCQ34663118-DCFA814E-57C6-4063-9EB1-EEEE4F996A6EQ34824179-E78476BB-D7BD-4A7F-A521-F68D9200E6A6Q35076748-81BF3632-1BED-4995-82D7-BA711531E9D6Q35093052-A1AA0635-1271-4DEC-AF7A-FEB680862AA1Q35192886-71A56F84-5105-4A8E-ABD2-7843006985D3Q35666057-647A8A14-9884-4E4C-A210-D65A12FB5E50Q35983587-AB04E018-A2B3-4F7A-971C-6980D0758F96Q36099119-4B789308-7EC5-45ED-97D7-2EDF7D1576D2Q36155445-1C96E36E-BFC3-4AA2-9080-07A85A609ECAQ36177537-E955178D-9F90-4EF6-93B9-E5B735E24421Q36315745-CC05F75A-26FB-4A8B-916F-CA2ADC6FD4E0Q36559942-AFE772FC-5001-4CE5-838B-49B379717FCAQ36571388-708484E0-47C2-4EBF-BCE9-87FFFDD947A7Q36694841-0CC5AB4B-C92A-4294-BAC6-F82274175237Q36789752-24D6B451-7369-4C40-9737-0F403DBB5E2BQ36798324-A20F5E27-AA19-4B13-B5DC-058E7578AA23Q36973720-0B2F1D1D-F399-4D39-8F82-20BA40F3E0ECQ37099729-1C99EA29-B6F2-4C5F-BD3D-621DB4CAC0B6Q37316023-A40F495A-9FCA-4C53-918E-A648D335015AQ37333743-E78D24E0-F617-407C-A989-E963D7301F02Q37336458-4C118D0A-C987-4A4A-BD8A-B63BFDAFFD51Q37701191-4AF38A6C-FB86-4089-A633-D0A57A5819F6Q38088037-D11C5ADA-FCE4-4756-BA6D-28942D5A53BE
P2860
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
@ast
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
@en
type
label
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
@ast
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
@en
prefLabel
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
@ast
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
@en
P2093
P2860
P50
P1433
P1476
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
@en
P2093
Denise L Kothe
Jiri Mestecky
Julie M Decker
Kenneth P Zammit
Maria G Salazar
Yingying Li
Zhiping Weng
Zina Moldoveanu
P2860
P304
P356
10.1016/J.VIROL.2006.10.017
P407
P50
P577
2006-11-13T00:00:00Z